AIDS

1. THINDWA D, Mwalukomo TS, Msefula J, Jambo KC, et al
   Risk factors for pneumococcal carriage in adults living with HIV on antiretroviral therapy in the infant pneumococcal vaccine era in Malawi.
   AIDS. 2022 Aug 22. pii: 00002030-990000000-00094.
   

   >> Share

   
   
2. WHITE HA, Baggaley RF, Okhai H, Patel H, et al
   The impact, effectiveness and outcomes of targeted screening thresholds for programmatic latent TB infection testing in HIV: cohort study results.
   AIDS. 2022 Aug 19. pii: 00002030-990000000-00096.
   

   >> Share

   
   
3. FINK DL, Oladele DA, Slack AJ, Odubela O, et al
   A multicentre observational study of HIV, TB and risk of chronic lung disease in urban west Africa.
   AIDS. 2022 Aug 19. pii: 00002030-990000000-00093.
   

   >> Share

   
   
4. KOBBE R, Schulze-Sturm U, Kurnaz P, Rau C, et al
   Vertical anti-SARS-CoV-2 monoclonal antibody transfer from mothers to HIV-exposed and unexposed infants.
   AIDS. 2022;36:1613-1615.
   

   >> Share

   
   
5. LONGHITANO A, Woolley I, Upjohn L, Korman T, et al
   New diagnosis of HIV with Cryptococcus neoformans infection presenting as a pleural syndrome.
   AIDS. 2022;36:1611-1613.
   

   >> Share

   
   
6. SATTA S, Hugo C, Sharma M, Rezek V, et al
   Mitoquinone mesylate attenuates brain inflammation in humanized mouse model of chronic HIV infection.
   AIDS. 2022;36:1609-1611.
   

   >> Share

   
   
7. LONDERO A, Fusi M, Cinausero M, Tascini C, et al
   Effects of the androgen receptor inhibitor enzalutamide on the pharmacokinetics of dolutegravir and tenofovir: a case report.
   AIDS. 2022;36:1603-1605.
   

   >> Share

   
   
8. TSUKAMOTO T
   HIV accelerates clonal hematopoiesis and cardiovascular aging.
   AIDS. 2022;36:1599-1601.
   

   >> Share

   
   
9. CONWAY B, Brenner BG
   Can simplified antiretroviral drug combination therapies resist resistance?
   AIDS. 2022;36:1597-1598.
   

   >> Share

   
   
10. TITANJI BK, Wang Z, Chen J, Hui Q, et al
    Soluble CD14-associated DNA methylation sites predict mortality among men with HIV infection.
    AIDS. 2022;36:1563-1571.
    

    >> Share

    
    
11. ETZKORN LH, Liu F, Urbanek JK, Heravi AS, et al
    Patterns of objectively measured physical activity differ between men living with and without HIV.
    AIDS. 2022;36:1553-1562.
    

    >> Share

    
    
12. SAVINELLI S, Wrigley Kelly NE, Feeney ER, O'Shea DB, et al
    Obesity in HIV infection: host-pathogen interaction.
    AIDS. 2022;36:1477-1491.
    

    >> Share

    
    
13. THEERASUWIPAKORN N, Rungpradubvong V, Chattranukulchai P, Siwamogsatham S, et al
    Higher prevalence of QTc interval prolongation among virologically suppressed older people living with HIV.
    AIDS. 2022 Aug 16. pii: 00002030-990000000-00090.
    

    >> Share

    
    
14. SMITH SA, Murray PM, Amancha PK, Ackerley CG, et al
    T cell activation and B cell interaction signatures in rectal tissues are associated with HIV replication in ex vivo model of infection.
    AIDS. 2022 Aug 16. pii: 00002030-990000000-00091.
    

    >> Share

    
    

    
    AIDS Res Hum Retroviruses

15. DUBE K, Agarwal H, Stockman JK, Auerbach JD, et al
    "I would absolutely need to know that my partner is still going to be protected": Perceptions of HIV Cure-Related Research among Diverse HIV Serodifferent Couples in the United States.
    AIDS Res Hum Retroviruses. 2022 Aug 16. doi: 10.1089/AID.2022.0036.
    

    >> Share

    
    
16. WANG X, Chen M, Ma S, Ding Y, et al
    HIV-1 Tat protein-mediated inflammatory response inhibits the erythroid hematopoietic support function of bone marrow mesenchymal stem cells.
    AIDS Res Hum Retroviruses. 2022 Aug 16. doi: 10.1089/AID.2022.0011.
    

    >> Share

    
    
17. HERNANDEZ-RUIZ VA, Erlandson KM, Amieva H, Avila-Funes JA, et al
    VACS index and Frailty: one part of the whole.
    AIDS Res Hum Retroviruses. 2022 Aug 16. doi: 10.1089/AID.2022.0075.
    

    >> Share

    
    
18. WEERASURIA M, Ko C, Ehm A, O'Bryan J, et al
    The impact of the COVID-19 pandemic on people with HIV in Victoria, Australia: 1 year later.
    AIDS Res Hum Retroviruses. 2022 Aug 16. doi: 10.1089/AID.2022.0048.
    

    >> Share

    
    
19. YEAGER S, Montoya JL, Burke L, Chow K, et al
    Patient and physician preferences regarding long-acting pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART): A mixed-methods study in Southern California, USA.
    AIDS Res Hum Retroviruses. 2022 Aug 16. doi: 10.1089/AID.2022.0029.
    

    >> Share

    
    
20. NEERGAARD R, Jones NL, Roebuck C, Rendle KA, et al
    "I know that I was a part of making a difference": Participant motivations for joining a cure-directed HIV trial with an analytical treatment interruption.
    AIDS Res Hum Retroviruses. 2022 Aug 18. doi: 10.1089/AID.2022.0040.
    

    >> Share

    
    
21. YU D, Liang B, Yang Y, Liu J, et al
    Prevalence of drug resistance and genetic transmission networks among HIV/AIDS patients with antiretroviral therapy failure in Guangxi, China.
    AIDS Res Hum Retroviruses. 2022 Aug 16. doi: 10.1089/AID.2021.0181.
    

    >> Share

    
    

    
    Antivir Ther

22. BELLO G, Kagoli M, Chipeta S, Auld A, et al
    Resistance levels to non-nucleoside reverse transcriptase inhibitors among pregnant women with recent HIV infection in Malawi.
    Antivir Ther. 2022;27:13596535221121225.
    

    >> Share

    
    

    
    BMC Cancer

23. GLASMEYER L, Mcharo RD, Torres L, Lennemann T, et al
    Long-term follow-up on HIV infected and non-infected women with cervical cancer from Tanzania: staging, access to cancer-directed therapies and associated survival in a real-life remote setting.
    BMC Cancer. 2022;22:892.
    

    >> Share

    
    

    
    BMJ

24. GANA T, Hunt LM
    Young women and anal sex.
    BMJ. 2022;378:o1975.
    

    >> Share

    
    

    
    Cell

25. SILVER JK, Booth GS, Chatterjee A, Crusto CA, et al
    Organizations in science and medicine must hold each other accountable for discriminatory practices.
    Cell. 2022;185:3073-3078.
    

    >> Share

    
    

    
    Clin Infect Dis

26. MARQUEZ C, Chen Y, Atukunda M, Chamie G, et al
    The Association Between Social Network Characteristics and Tuberculosis Infection Among Adults in Nine Rural Ugandan Communities.
    Clin Infect Dis. 2022 Aug 19. pii: 6671580. doi: 10.1093.
    

    >> Share

    
    
27. DHARAN NJ, Jin F, Vaccher S, Bavinton B, et al
    Characteristics of HIV seroconversions in a large prospective implementation cohort study of oral HIV pre-exposure prophylaxis in men who have sex with men (EPIC-NSW).
    Clin Infect Dis. 2022 Aug 19. pii: 6671581. doi: 10.1093.
    

    >> Share

    
    
28. MASTROROSA I, Pinnetti C, Brita AC, Mondi A, et al
    Declining prevalence of HIV-associated neurocognitive disorders in more recent years and associated factors, in a large cohort of ART-treated HIV-infected individuals.
    Clin Infect Dis. 2022 Aug 19. pii: 6671582. doi: 10.1093.
    

    >> Share

    
    
29. SIBERRY GK, Mofenson LM, Calmy A, Reddy UM, et al
    Use of Ritonavir-boosted Nirmatrelvir in Pregnancy.
    Clin Infect Dis. 2022 Aug 17. pii: 6668958. doi: 10.1093.
    

    >> Share

    
    
30. SCHNITTMAN SR, Lu MT, Mayrhofer T, Burdo TH, et al
    Cytomegalovirus IgG Titer and Coronary Artery Disease in People with HIV.
    Clin Infect Dis. 2022 Aug 17. pii: 6668874. doi: 10.1093.
    

    >> Share

    
    
31. OURSLER KK, Marconi VC, Wang Z, Xu K, et al
    Epigenetic Age Acceleration Markers Are Associated with Physiologic Frailty and All-cause Mortality in People with HIV.
    Clin Infect Dis. 2022 Aug 16. pii: 6667629. doi: 10.1093.
    

    >> Share

    
    
32. PERSON AK, Armstrong WS, Evans T, Fangman JJ, et al
    Principles for Ending HIV as an Epidemic in the United States: A Policy Paper of IDSA and HIVMA.
    Clin Infect Dis. 2022 Aug 15. pii: 6662275. doi: 10.1093.
    

    >> Share

    
    
33. WEITZMAN ER, Sherman AC, Levy O
    Pediatric SARS-CoV-2 Vaccines: Perceptions and Attitudes from the FDA Public Commentary.
    Clin Infect Dis. 2022 May 17. pii: 6586838. doi: 10.1093.
    

    >> Share

    
    
34. SHERMAN AC, Rouphael N, Baden LR
    COVID-19 Vaccine Trials (and Tribulations): How to improve the process of clinical trials in a pandemic.
    Clin Infect Dis. 2022 Apr 18. pii: 6569988. doi: 10.1093.
    

    >> Share

    
    

    
    HIV Med

35. OCEGUERA S, Tulloch K, Tkachuk S
    Post-partum contraception in women living with HIV.
    HIV Med. 2022 Aug 16. doi: 10.1111/hiv.13371.
    

    >> Share

    
    
36. SHAFRAN SD, Hughes CA
    Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance.
    HIV Med. 2022 Aug 16. doi: 10.1111/hiv.13376.
    

    >> Share

    
    

    
    J Acquir Immune Defic Syndr

37. LLIBRE JM, Lopez Cortes LF, Aylott A, Wynne B, et al
    Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2.
    J Acquir Immune Defic Syndr. 2022;91:73-78.
    

    >> Share

    
    
38. GROENENDIJK AL, Vos WAJW, Dos Santos JC, Rokx C, et al
    Non-AIDS-events in individuals with spontaneous control of HIV-1: a systematic review.
    J Acquir Immune Defic Syndr. 2022 Aug 15. pii: 00126334-990000000-00090.
    

    >> Share

    
    
39. TSENG AS, Sambai B, Monroe-Wise A, Mbogo LW, et al
    Assisted partner services for people who inject drugs: Index characteristics associated with untreated HIV in partners.
    J Acquir Immune Defic Syndr. 2022 Aug 15. pii: 00126334-990000000-00089.
    

    >> Share

    
    
40. ANDERSON AM, Bhondoekhan F, Curanovic D, Connelly MA, et al
    Higher soluble CD163 in blood is associated with significant depression symptoms in men with HIV.
    J Acquir Immune Defic Syndr. 2022 Aug 15. pii: 00126334-990000000-00093.
    

    >> Share

    
    
41. STEINERT JI, Shenderovich Y, Smith M, Zhou S, et al
    Economic wellbeing and associated mediating pathways to improved antiretroviral therapy adherence among adolescents living with HIV: A prospective cohort study in South Africa.
    J Acquir Immune Defic Syndr. 2022 Aug 15. pii: 00126334-990000000-00091.
    

    >> Share

    
    
42. JIAMSAKUL A, Gani Y, Avihingsanon A, Azwa I, et al
    Mortality after loss to follow-up - a linkage study of people living with HIV in Thailand and Malaysia.
    J Acquir Immune Defic Syndr. 2022 Aug 15. pii: 00126334-990000000-00094.
    

    >> Share

    
    
43. DRAGONI F, Rossetti B, Lombardi F, Raffaelli CS, et al
    Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy.
    J Acquir Immune Defic Syndr. 2022 Aug 15. pii: 00126334-990000000-00092.
    

    >> Share

    
    
44. CALZA L, Bon I, Pensalfine G, Vitale S, et al
    CHANGES IN SERUM INFLAMMATORY MARKERS IN ANTIRETROVIRAL THERAPY-NAIVE HIV-INFECTED PATIENTS STARTING DOLUTEGRAVIR/LAMIVUDINE OR TENOFOVIR ALAFENAMIDE/EMTRICITABINE/BICTEGRAVIR.
    J Acquir Immune Defic Syndr. 2022 Aug 18. pii: 00126334-990000000-00095.
    

    >> Share

    
    
45. ESBER A, Dear N, Shah N, Kibuuka H, et al
    Virologic impact of the dolutegravir transition: prospective results from the multinational African Cohort Study.
    J Acquir Immune Defic Syndr. 2022 Aug 3. pii: 00126334-990000000-00084.
    

    >> Share

    
    
46. BRUZZESI E, Galli L, Poli A, Bossolasco S, et al
    PREVALENCE AND RISK FACTORS OF ANAL HPV INFECTION IN MSM LIVING WITH HIV: IDENTIFYING THE TARGET GROUPS TO PRIORITIZE FOR IMMUNIZATION.
    J Acquir Immune Defic Syndr. 2022 Jul 11. pii: 00126334-900000000-95605.
    

    >> Share

    
    
47. CHENCINER L, Symonds M, Dissanayake O, Hunter A, et al
    Lymphocyte-CRP Ratio and CRP-Albumin Ratio as Potential Inflammation Markers in Adults With HIV.
    J Acquir Immune Defic Syndr. 2022;91:e1-e3.
    

    >> Share

    
    
48. SOLANKE T, Kamau F, Esterhuizen T, Maartens G, et al
    Concentrations of Efavirenz, Tenofovir, and Emtricitabine in Obesity: A Cross-Sectional Study.
    J Acquir Immune Defic Syndr. 2022;91:101-108.
    

    >> Share

    
    
49. MOLINA JM, Yazdanpanah Y, Afani Saud A, Bettacchi C, et al
    Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.
    J Acquir Immune Defic Syndr. 2022;91:68-72.
    

    >> Share

    
    
50. LEWIS MA, Harshbarger C, Bann C, Marconi VC, et al
    Effectiveness of an Interactive, Highly Tailored "Video Doctor" Intervention to Suppress Viral Load and Retain Patients With HIV in Clinical Care: A Randomized Clinical Trial.
    J Acquir Immune Defic Syndr. 2022;91:58-67.
    

    >> Share

    
    
51. BEESHAM I, Mansoor LE, Joseph Davey DL, Palanee-Phillips T, et al
    Brief Report: Quantifiable Plasma Tenofovir Among South African Women Using Daily Oral Pre-exposure Prophylaxis During the ECHO Trial.
    J Acquir Immune Defic Syndr. 2022;91:26-30.
    

    >> Share

    
    
52. KAMIRE V, Magut F, Khagayi S, Kambona C, et al
    HIV Risk Factors and Risk Perception Among Adolescent Girls and Young Women: Results From a Population-Based Survey in Western Kenya, 2018.
    J Acquir Immune Defic Syndr. 2022;91:17-25.
    

    >> Share

    
    

    
    J Clin Invest

53. FOX DA
    Immunodeficiency and autoimmunity: companions not opposites.
    J Clin Invest. 2022;132.
    

    >> Share

    
    

    
    J Infect Dis

54. HWA SH, Snyman J, Bernstein M, Ganga Y, et al
    HIV viremia is associated with compromised SARS-CoV-2 Beta variant neutralization.
    J Infect Dis. 2022 Aug 17. pii: 6670446. doi: 10.1093.
    

    >> Share

    
    

    
    J Med Virol

55. KHELLAF L, Bouscarat F, Burrel S, Fidouh N, et al
    Novel mutations in antiviral multiresistant HSV-2 genital lesion: a case report.
    J Med Virol. 2022 Aug 16. doi: 10.1002/jmv.28070.
    

    >> Share

    
    

    
    J Virol

56. ANANG S, Richard J, Bourassa C, Goyette G, et al
    Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound.
    J Virol. 2022 Aug 18:e0063622. doi: 10.1128/jvi.00636.
    

    >> Share

    
    
57. WOODBURN BM, Kanchi K, Zhou S, Colaianni N, et al
    Characterization of Macrophage-Tropic HIV-1 Infection of Central Nervous System Cells and the Influence of Inflammation.
    J Virol. 2022 Aug 17:e0095722. doi: 10.1128/jvi.00957.
    

    >> Share

    
    

    
    JAMA

58. NELSON KM, Skinner A, Underhill K
    Minor Consent Laws for Sexually Transmitted Infection and HIV Services.
    JAMA. 2022;328:674-676.
    

    >> Share

    
    

    
    Lancet

59. THORNTON J
    Botswana's HIV/AIDS success.
    Lancet. 2022;400:480-481.
    

    >> Share

    
    

    
    Nat Rev Immunol

60. HAYNES BF, Wiehe K, Borrrow P, Saunders KO, et al
    Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies.
    Nat Rev Immunol. 2022 Aug 12. pii: 10.1038/s41577-022-00753.
    

    >> Share

    
    

    
    Pediatr Infect Dis J

61. LIYANAGE M, Nikanjam M, McFadyen L, Vourvahis M, et al
    Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life.
    Pediatr Infect Dis J. 2022 Aug 9. pii: 00006454-990000000-00156.
    

    >> Share

    
    

    
    PLoS One

62. ARYAIE M, Sharifi H, Saber A, Salehi F, et al
    Longitudinal causal effect of modified creatinine index on all-cause mortality in patients with end-stage renal disease: Accounting for time-varying confounders using G-estimation.
    PLoS One. 2022;17:e0272212.
    

    >> Share

    
    
63. KATENDE A, Nakiyingi L, Andia-Biraro I, Katairo T, et al
    Antiretroviral therapy initiation and outcomes of hospitalized HIV-infected patients in Uganda-An evaluation of the HIV test and treat strategy.
    PLoS One. 2022;17:e0268122.
    

    >> Share

    
    
64. GORDON TP, Talbert M, Mugisha MK, Herbert AE, et al
    Factors associated with HIV viral suppression among adolescents in Kabale district, South Western Uganda.
    PLoS One. 2022;17:e0270855.
    

    >> Share

    
    
65. AHMED M, Seid S, Yimer A, Seid A, et al
    Uptake of premarital HIV testing and associated factors among women who had autonomous versus non autonomous marriage in Ethiopia: A nationwide study.
    PLoS One. 2022;17:e0271879.
    

    >> Share

    
    
66. KAGGIAH A, Wilson K, Richardson BA, Kinuthia J, et al
    Prevalence and correlates of intimate partner violence among women with HIV in serodifferent relationships in Nairobi, Kenya.
    PLoS One. 2022;17:e0272640.
    

    >> Share

    
    
67. AL-KOLLA R, Grifoni A, Crotty S, Sette A, et al
    Design and validation of HIV peptide pools for detection of HIV-specific CD4+ and CD8+ T cells.
    PLoS One. 2022;17:e0268370.
    

    >> Share

    
    
68. ARAIA ZZ, Kibreab F, Kibrom AA, Mebrahtu AH, et al
    Determinants of unsuccessful tuberculosis treatment outcome in Northern Red Sea region, Eritrea.
    PLoS One. 2022;17:e0273069.
    

    >> Share

    
    

    
    PLoS Pathog

69. MORRIS SE, Strehlau R, Shiau S, Abrams EJ, et al
    Healthy dynamics of CD4 T cells may drive HIV resurgence in perinatally-infected infants on antiretroviral therapy.
    PLoS Pathog. 2022;18:e1010751.
    

    >> Share

    
    
70. JUNG KL, Choi UY, Park A, Foo SS, et al
    Single-cell analysis of Kaposi's sarcoma-associated herpesvirus infection in three-dimensional air-liquid interface culture model.
    PLoS Pathog. 2022;18:e1010775.
    

    >> Share

    
    

    
    Vaccine

71. XIRIDOU M, Adam P, Meiberg A, Visser M, et al
    The impact of the COVID-19 pandemic on hepatitis B virus vaccination and transmission among men who have sex with men: A mathematical modelling study.
    Vaccine. 2022 Jul 4. pii: S0264-410X(22)00847.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share